Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
ADI is highlighting the testimonies of those undertaking health tourism to access Alzheimer's disease treatments across the world. Recent significant advancements have led to the development of disease-modifying therapies designed to slow progression. However, access remains highly fragmented, leading to the the onset of people travelling for treatment, or health tourism, for those that have the means.